PCSK9 inhibitor study for aortic stenosis patients
Part of Heart & circulation clinical trials.
This trial tests whether a PCSK9 inhibitor (a cholesterol-lowering medicine) can slow the progression of calcific aortic stenosis, a heart valve condition. It may be an option for people with mild or moderate valve narrowing who are not yet ready for surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 85 years old
- You have mild or moderate calcific aortic stenosis (your heart valve is thickened and narrowed but not severely so)
- Your LDL cholesterol is between 2.6 and 4.9 mmol/L, or lipoprotein(a) is high (over 30 mg/dL), or you already take a statin for high cholesterol
- You do not need immediate valve replacement surgery
- You can commit to taking the study drug for up to 24 months and follow the study schedule
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding PCSK9 inhibitor injections (to statin treatment) can slow or improve calcific aortic valve stenosis, a condition where the heart’s aortic valve becomes stiff and narrowed. It’s aimed at adults with mild-to-moderate disease or certain people with severe disease but no symptoms.
This trial tests a new valve device placed through a small tube (catheter) to treat severe aortic stenosis, a condition where the aortic valve is narrowed and doesn't open fully. It's for patients who cannot have traditional open-heart surgery.
This trial tests if a medication called PCSK-9 inhibitor can slow the progression of calcified aortic valve disease, a condition where the heart's aortic valve becomes stiff and narrow. It is for people who also have heart disease or very high cholesterol that hasn't been controlled well with statins.
This trial tests a new pill, ataciguat, to slow down the progression of moderate calcific aortic valve stenosis (a condition where your aortic valve stiffens). If you have moderate valve narrowing and meet the other criteria, participation could help find a way to delay needing surgery.
This trial tests if the drug vericiguat can slow down the buildup of calcium in the aortic valve, which causes it to narrow and stiffen. If you have mild-to-moderate aortic valve stenosis and meet the other criteria, this study may help protect your valve from getting worse.
This study looks at blood and/or body signals (called biomarkers) to understand why aortic valve narrowing may worsen and what outcomes people have. You may be able to help researchers by undergoing regular heart care plus additional testing like MRI or CT if you qualify.
Hear when a new Aortic Stenosis, Calcific trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.